Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

Biotech bigwig Gilead Sciences, Inc. (GILD) is scheduled to report second-quarter 2025 results on Aug. 7, after market close.

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

According to Gilead Sciences, no patients with M184V/I who received Biktarvy had HIV RNA ≥50 copies/mL at week 48. No cases of treatment-emergent resistance were reported in the final analysis.

Biktarvy is a complete HIV treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available ...

Biktarvy, which is used to treat HIV, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

Biktarvy contains three medicines: bictegravir, emtricitabine, and tenofovir alafenamide. Two of these medicines, emtricitabine and tenofovir alafenamide, have been used to treat HIV for many years.

Biktarvy is used in adults and certain children to treat HIV-1 (the most common type of HIV.) Children receiving Biktarvy must weigh at least 14 kilograms (kg).